NCT06321562CompletedPhase 1
Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 19 Apr 2024
- Start date
- 9 Feb 2023
- Lead sponsor
- Eyed Pharma
- Diseases
- Glaucoma
- NCT number
- NCT06321562
- EU CT number
- 2024-511254-51-00
- EudraCT number
- 2020-002354-24
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 18
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire de Liège Coordinator of this site? Confirm its status | Liège | Belgium | Completed |
| Internationale Innovative Ophthalmochirurgie GbR (I.I.O.) Coordinator of this site? Confirm its status | Duesseldorf | Germany | Completed |
| Universitaetsklinikum Heidelberg AöR Coordinator of this site? Confirm its status | Heidelberg | Germany | Completed |
| Otto Von Guericke Universitaet Magdeburg Coordinator of this site? Confirm its status | Magdeburg | Germany | Completed |
| Knappschaftsklinikum Saar GmbH Coordinator of this site? Confirm its status | Sulzbach | Germany | Completed |
| Universitaetsklinikum Tuebingen AöR Coordinator of this site? Confirm its status | Tuebingen | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.